According to Fortune Business Insights, the global cannabidiol market was valued at roughly $16.52 billion in 2025 and is expected to climb to about $24.61 billion in 2026. From there, the report forecasts an aggressive expansion to approximately $382.04 billion by 2034, implying a compound annual growth rate (CAGR) of nearly 40.89% across the 2026–2034 forecast window. This pace of growth reflects a market still in its early stages of commercialization, where regulatory change, consumer education, and product innovation are compounding to unlock demand across multiple industries.
CBD is a non-psychoactive compound derived from cannabis or hemp plants, most commonly hemp because of its naturally elevated CBD concentration. It is frequently confused with THC, the psychoactive compound found in the same plant family, and much of the market's growth strategy revolves around correcting that misconception. The compound has drawn attention for its potential in easing anxiety, reducing inflammation and pain, and helping manage seizure disorders, which has fueled its adoption across pharmaceuticals, food and beverages, cosmetics, and pet care.
Regional Landscape
North America is the clear leader in this market, accounting for close to 48% of global revenue in 2025 and projected to reach nearly $11.8 billion in 2026. The United States alone is expected to approach $9.8 billion in 2026 and could reach roughly $78.7 billion by 2032, driven by loosening state and federal restrictions and rising consumer comfort with CBD products.
Europe holds the second-largest share, with the market valued at roughly $4.2 billion in 2025 and projected to reach about $6.3 billion in 2026, led by strong demand for CBD vapes, edibles, and smokable formats as consumers move away from traditional tobacco. The UK and Germany are the standout national markets within the region.
Asia Pacific, while smaller, is developing quickly. The region held about 17% of global share in 2025 and is expected to reach roughly $4.3 billion in 2026, with China, Japan, and India representing emerging growth pockets as legalization frameworks slowly expand. South America and the Middle East & Africa remain the smallest regional segments, constrained by inconsistent regulation, though countries such as Uruguay, Colombia, Peru, and Lebanon have created pathways for medicinal or recreational use that are gradually opening the category.
Get a Free Sample PDF - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/cannabidiol-cbd-market-103215
Segmentation Trends
By source, marijuana-derived CBD is expected to hold the larger share of the market in 2026, at just over 56%, largely because of its wider availability in North America and Europe. Hemp-based CBD, however, is gaining traction as a legally simpler and increasingly popular alternative, particularly in regions with stricter cannabis laws.
By application, pharmaceuticals lead the market, expected to capture close to 37% of global revenue in 2026. This is attributed to CBD's therapeutic properties, including pain relief and neuroprotective potential, which align with the pharmaceutical industry's broader push toward plant-based and natural alternatives to conventional medicine. Food and beverages, cosmetics, and pet care round out the other major application categories, each benefiting from growing interest in "wellness" positioned consumer products.
Growth Drivers and Restraints
Government approvals are a central growth driver. Regulatory bodies such as the U.S. Food and Drug Administration have acknowledged CBD's potential across food and non-food uses, even as they continue refining oversight frameworks. This regulatory softening is encouraging manufacturers to formulate new CBD-infused products and pursue mergers and acquisitions, such as British Cannabis's 2024 acquisition of Goodbody Botanicals, to expand product portfolios and geographic reach.
On the restraint side, the market continues to face uneven consumer awareness and lingering confusion between CBD and psychoactive THC, particularly in developing economies across Asia and the Middle East. Marketing barriers and inconsistent regulatory treatment across borders continue to slow adoption in these regions, even as companies invest in consumer education and clearer product labeling.
Competitive Landscape
The market includes a mix of established cannabis companies and consumer product entrants. Key players named in the report include Aurora Cannabis, Medical Marijuana Inc., Medterra CBD, Isodiol International, Elixinol Global, ENDOCA, CV Sciences, Folium Biosciences, Cannoid, and Pharmahemp. Recent product activity includes Aurora Cannabis's early-2024 launch of cannabis-infused ready-to-drink beverages and Jublee CBD's rollout of CBD-infused skincare lines, both signaling a broader trend of established players diversifying beyond oils and tinctures into functional consumer goods.
Outlook
With a projected CAGR approaching 41% through 2034, the CBD market's trajectory hinges largely on continued regulatory liberalization, expanding pharmaceutical applications, and manufacturers' ability to close awareness gaps in underpenetrated regions. North America is likely to remain the dominant regional market, but Asia Pacific and South America represent the higher-growth-potential frontiers as legal frameworks mature.